Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients

Institute of Pathology and Urologic Clinics, University of Basel, Switzerland.
Human Pathlogy (Impact Factor: 2.81). 06/2000; 31(5):578-83.
Source: PubMed

ABSTRACT The prognosis of prostate cancer is mainly determined by the presence or absence of metastases. Nevertheless, the metastatic pathways in prostate cancer are not entirely understood. Among 19,316 routine autopsies performed from 1967 to 1995 on men older than 40 years of age, the reports from those 1,589 (8.2%) with prostate cancer were analyzed. Hematogeneous metastases were present in 35% of 1,589 patients with prostate cancer, with most frequent involvement being bone (90%), lung (46%), liver (25%), pleura (21%), and adrenals (13%). Several lines of evidence suggested the existence of a backward metastatic pathway through veins from the prostate to the spine in addition to classical hematogeneous tumor spread via the vena cava. First, there was an inverse relationship between spine and lung metastases, suggesting that metastasis to the spine is independent of lung metastasis. Second, the maximum frequency of spine involvement occurred in smaller tumors (4 to 6 cm) as compared with the maximum spread to lung (6 to 8 cm) and liver (>8 cm), suggesting that spine metastases precede lung and liver metastases in many prostate cancers. Third, there was a gradual decrease in spine involvement from the lumbar to the cervical level (97% v 38%), which is consistent with a subsequent upward metastatic spread along spinal veins after initial lumbar metastasis. The results of this study show that bone, lung, and liver are the most frequent sites of distant prostate cancer metastases. Besides the cava-type of metastasis through lung passage, there are strong arguments for the existence and clinical significance of a backward venous spread to the spine, which is likely to occur early in the metastatic process.

  • Source
    • "Bone is often a target for breast cancer metastases (Chambers et al., 2002) and up to 90% of metastatic prostate cancer patients have lesions in the bones upon autopsy (Bubendorf et al., 2000). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The metastatic cascade comprises the following steps in sequential manner: the future metastatic cell has to leave the primary tumor mass, degrade the surrounding extracellular matrix, extravasate and circulate within in the bloodstream. Thereafter it has to attach to the endothelium of a target organ, intravasate into the connective tissue and has to proliferate to form a clinically detectable metastasis. We overview the in vitro microfluidic platforms modelling the metastatic cascade and the evolution towards systems capable of recapitulating all the steps by a single comprehensive model. Copyright © 2015. Published by Elsevier GmbH.
    Progress in Histochemistry and Cytochemistry 02/2015; 49(4). DOI:10.1016/j.proghi.2015.01.001 · 5.91 Impact Factor
  • Source
    • "The " PSA test " has reduced mortality of men [23], however, has come under criticism due to the lack of knowledge regarding the functional contribution of this protease in cancer progression [24]. Many prostate tumors remain undetected and/or progress to end-stage disease , typically bone metastasis, which is incurable [25]. Other prostate-expressed KLKs (KLK1–2, KLK4–5, KLK10–11, and KLK15) show promise as adjunct or independent biomarkers for this disease and, along with KLK3, functional assessment has highlighted their potential as targets for novel prostate cancer therapy [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rapidly developing proteomic tools are improving detection of deregulated kallikrein-related peptidase (KLK) expression, at the protein level, in prostate and ovarian cancer, as well as facilitating the determination of functional consequences downstream. Mass spectrometry (MS)-driven proteomics uniquely allows for the detection, identification and quantification of thousands of proteins in a complex protein pool, and this has served to identify certain KLKs as biomarkers for these diseases. In this review we describe applications of this technology in KLK biomarker discovery, and elucidate MS-based techniques which have been used for unbiased, global screening of KLK substrates within complex protein pools. Although MS-based KLK degradomic studies are limited to date, they helped to discover an array of novel KLK substrates. Substrates identified by MS-based degradomics are reported with improved confidence over those determined by incubating a purified or recombinant substrate and protease of interest, in vitro. We propose that these novel proteomic approaches represent the way forward for KLK research, in order to correlate proteolysis of biological substrates with tissue-related consequences, toward clinical targeting of KLK expression and function for cancer diagnosis, prognosis and therapies. This article is protected by copyright. All rights reserved.
    PROTEOMICS - CLINICAL APPLICATIONS 06/2014; 8(5-6). DOI:10.1002/prca.201300098 · 2.68 Impact Factor
  • Source
    • ". Hematogenous metastases are present in 35% of patients with prostate cancer, with most frequent involvement sites being bone (90%), lung (46%), liver (25%), pleura (21%), and adrenals (13%) [2] [3] [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We describe the case of a patient with prostate cancer, ascites, omental and bone metastases, an extremely rare clinical variant that warrants further investigation, and review the relevant literature.
    Journal of Advanced Research 05/2014; 6(3). DOI:10.1016/j.jare.2014.05.002
Show more